Infliximab Clearance in Relation to Disease Activity During Induction and Maintenance Therapy of Acute Severe and Ambulatory Pediatric Ulcerative Colitis.
出版信息
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):7-8.
Abstract
摘要
相似文献
1
Infliximab Clearance in Relation to Disease Activity During Induction and Maintenance Therapy of Acute Severe and Ambulatory Pediatric Ulcerative Colitis.英夫利昔单抗在急性重度和非卧床型小儿溃疡性结肠炎诱导和维持治疗期间的清除率与疾病活动度的关系
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):7-8.
2
Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.中度至重度溃疡性结肠炎患儿英夫利昔单抗诱导和维持治疗：回顾性多中心研究
Adv Clin Exp Med. 2017 Jan-Feb;26(1):57-61. doi: 10.17219/acem/42197.
3
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.急性重度溃疡性结肠炎患者与中度重度溃疡性结肠炎患者诱导英夫利昔单抗水平比较。
Aliment Pharmacol Ther. 2016 Jun;43(12):1293-9. doi: 10.1111/apt.13631. Epub 2016 Apr 19.
4
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.系统评价和荟萃分析：急性重度溃疡性结肠炎的最佳挽救治疗。
Inflamm Bowel Dis. 2019 Jun 18;25(7):1169-1186. doi: 10.1093/ibd/izy383.
5
Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.诱导后英夫利昔单抗谷浓度与儿童溃疡性结肠炎临床转归的疾病活动度。
United European Gastroenterol J. 2020 May;8(4):425-435. doi: 10.1177/2050640620912877. Epub 2020 Mar 12.
6
Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis.检查英夫利昔单抗挽救治疗急性重度溃疡性结肠炎后的维持治疗。
J Gastroenterol Hepatol. 2018 Jan;33(1):226-231. doi: 10.1111/jgh.13850.
7
Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.托法替尼治疗急性重度溃疡性结肠炎的补救治疗：真实世界经验。
J Crohns Colitis. 2020 Jul 30;14(7):1026-1028. doi: 10.1093/ecco-jcc/jjaa018.
8
Infliximab Rescue Therapy in Pediatric Severe Colitis.英夫利昔单抗在儿科重度结肠炎中的挽救治疗。
J Pediatr Surg. 2023 Oct;58(10):1893-1897. doi: 10.1016/j.jpedsurg.2023.05.025. Epub 2023 May 29.
9
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.英夫利昔单抗与维得利珠单抗治疗炎症性肠病患者的疗效和安全性比较：系统评价和荟萃分析。
BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1.
10
Infliximab for induction and maintenance therapy for ulcerative colitis.英夫利昔单抗用于溃疡性结肠炎的诱导和维持治疗。
N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516.
引用本文的文献
1
Highlights in Ulcerative Colitis From Digestive Disease Week 2023: Commentary.2023年消化系统疾病周溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):13-16.
本文引用的文献
1
Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis.多中心队列研究：英夫利昔单抗在儿童急性重度溃疡性结肠炎中的药代动力学和治疗反应。
Clin Gastroenterol Hepatol. 2023 May;21(5):1338-1347. doi: 10.1016/j.cgh.2022.08.016. Epub 2022 Aug 27.
2
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.英夫利昔单抗诱导和维持治疗中重度溃疡性结肠炎患儿。
Clin Gastroenterol Hepatol. 2012 Apr;10(4):391-9.e1. doi: 10.1016/j.cgh.2011.11.026. Epub 2011 Dec 8.
Zotero 插件